Upcoming Meetings

​​​​​​

​

​​​

October 3

Presentation by Dr. Jose Avitia, New Mexico Cancer Center: How Long Should Hormone Therapy Last? What Recent Research Tells Us. 

Join Zoom Meeting
https://us02web.zoom.us/j/83075078011?pwd=Xc8qbILRgnROuExIbLd4HYFp8hioO7.1

Meeting ID: 830 7507 8011
Passcode: 841308

​

Presenter Bio: Dr. José W. Avitia was born and raised in New Mexico and has dedicated his career to serving his community. He completed his undergraduate studies at the University of New Mexico (UNM), earned his medical degree at the University of Illinois in Chicago, returned to UNM for his residency, and completed fellowship
training in hematology and oncology at the University of Oklahoma. Dr. Avitia is the Director of Prostate Cancer Research at the New Mexico Cancer Center, where he leads clinical trials to bring cutting-edge treatments to local patients. His mission is to provide world-class cancer care close to home, offering hope and compassionate support to patients and their families throughout New Mexico.

 

October 17

Sharing session

 

November 7

Presentation by Bob Watson, a Lead Researcher of the Estriodol Initiative: Transdermal Estradiol for Androgen Deprivation Therapy

 

A resident of New Mexico, Bob Watson (PhD), will present pros and cons of using transdermal estradiol patches or gels to treat prostate cancer by suppressing testosterone and PSA equally as well as Lupron ADT, but with no increased cardiovascular events, and with far fewer adverse side effects (such as hot flashes, osteoporosis, and osteoporotic fractures), and at significantly reduced costs.

 

Presenter Bio: Bob Watson is 70 years old and is a retired PhD nuclear engineer. He currently works as a patent agent writing patent applications. He has been a prostate cancer patient for 2 years now. His Gleason score at diagnosis was 4+3, and MRI scans confirmed 2 tumors in his prostate. His peak PSA reached 10, at which point he took Dutasteride for 5 months. His PSA dropped from 10 to 2.4 over that time. Next, he did SBRT radiation treatment (5 sessions) and then did Orgovyx ADT treatment for 6 months, while simultaneously taking high-dose, transdermal estradiol gel (1% E2 concentration) to prevent osteoporosis. His lowest PSA was undetectable (< 0.02). He had no hot flashes while on ADT, and his bone mineral density increased by 10% during the 8 months that he was using transdermal estradiol gel.

​

November 21

Sharing session

​

December 5

Presentation by John Moser, Artera AI Prostate Cancer: Understanding Your Prostate Cancer--How AI Tools Help Patients and Doctors

​

What is the ArteraAI Prostate Test?

 

John will talk about a new kind of technology that uses artificial intelligence (AI) to help doctors and patients better understand prostate cancer: the ArteraAI Prostate Test.

 

This technology looks closely at a patient's existing biopsy, so no new tests or procedures are needed. Combined with other health information, it can help show how a cancer may behave over time and which treatments are more likely to help a specific patient. This test is included in national treatment guidelines for prostate cancer, and it's covered for eligible Medicare patients.

 

John will explain this in plain language and talk through a question many patients face after diagnosis: "What does my cancer mean for me, and which treatment is most likely to help?" There will be plenty of time for questions, and John will share how patients can bring up tools like this with their own doctor.

​

Presenter Bio:

John Moser is a Swedish-born Albuquerque resident whose life has taken him around the world. Having lived in several countries and learned multiple languages along the way, John jokes that the latest language he has learned to speak is “prostate cancer.”

 

John works with ArteraAI, a company that builds AI tools to help doctors and patients make more personal treatment decisions after a cancer diagnosis.

​

December 19

Annual Meeting/Potluck